LFRP

AcronymDefinition
LFRPLicensing and Funded Research Program (Dyax Corp.; Cambridge, MA)
LFRPLassa Fever Research Project (Segbwema, Sierra Leone)
LFRPLiving Free Radical Polymerisation
References in periodicals archive ?
In addition, the third quarter and nine months of 2012 reflect an expense decline due to lower personnel costs after the February 2012 re-alignment around the angioedema and LFRP franchises, and a reduction in pass-through license fees paid by Dyax licensees under the LFRP.
This press release contains forward-looking statements, including statements regarding the prospects for the LFRP portfolio and increases in the KALBITOR patient base, treatment rates and sales, prospects for KALBITOR and DX-2930 to treat a broader range of angioedemas, projected KALBITOR sales and revenues for 2012, and projected cash flow break-even in 2013.
The 2012 research and development expenses primarily relate to the following Dyax research and development initiatives: 1) KALBITOR post-marketing requirements; 2) development of a single-injection formulation of KALBITOR; 3) a clinical study of the use of ecallantide for the treatment of ACE inhibitor-induced angioedema, including costs related to the discontinuation and close-out of Dyax's Phase 2 study in this indication; 4) development costs associated with DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein; and 5) pass-through license fees paid by Dyax licensees under the LFRP.